ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2168

The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis

Gilad Halpert1, Ori Moskovitch1, Adi Anaki2, Tal Caller1, Omer Gendelman1, Abdulla watad1, Ruty Mehrian-Shai1, Rachella Popovtzer2, Boris Guilbord1, Ori Segal1 and Howard AMITAL1, 1Sheba Medical Center, Ramat Gan, Israel, 2Bar Ilan University, Ramat Gan, Israel

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2141–2176) RA – Treatments Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The use of biological treatment in patients with rheumatoid arthritis (RA) can induce non-specific immune suppression, which might result in higher rates of infections. Therefore, there are still unmet needs to develop more specific and safe therapies in the management of RA patients. Accumulating evidence suggests that extracellular vesicles (EVs) may play a role in the modulation and maintenance of autoimmune processes. In the current study, we aimed to prove that isolation of circulating autologous ’tissue-specific’ homing EVs from RA patients – may improve the delivery of current FDA-approved anti-inflammatory drugs, which will be encapsulated into these EVs. We assume that the drug-loaded EVs will find their way specifically to the inflamed tissue, following their administration to the same patient (Figure 1).

Methods: Plasma/serum-derived EVs had been isolated from arthritic mice (collagen-induced arthritis [CIA] model) and RA patients using: ultrafiltration, commercial exosome purification kit (NORGEN BIOTEK CORP) and size exclusion chromatography techniques. Characterization of these EVs have been conducted using nanoparticle tracking analysis, transition electron microscopy and western blot analysis. The expression of ’tissue-specific homing receptors’ such as integrins, on plasma/serum-derived EVs isolated from arthritic mice (CIA model) or RA patients, had been examined, using WB analysis. EVs were labelled using DiR fluorescent dye and their potential in-vivo migration towards inflamed synovia, had been explored in collagen antibody-induced arthritis (CAIA) model, using In Vivo Imaging System (IVIS). Cellular uptake of RA patients-derived labelled EVs have been conducted using SW982, a human synovial cells.

Results: We found that autologous labeled EVs, derived from blood of arthritic mice with CAIA, can migrate towards inflamed synovia. Moreover, we show that these EVs strongly expresses glucose transporter 1 (mGLUT1) which in turn, improve their therapeutic potential to be loaded with anti-inflammatory drugs using glucose-coated gold nanoparticles (GNPs). Finally, we show that EVs derived from plasma of RA patients expresses the joint/synovia-specific homing receptor αVβ3 integrin and can be taken up by LPS/TNFα-induced activated human synovial cell line in vitro.

Conclusion: Overall, we show the potential of autologous circulating EVs of RA patients to serves as natural nano-carrier for current FDA-approved drugs. We believe that this strategy will increase the specificity and efficiency of current treatment, possibly reducing side effects and will improve the quality of life of RA patients and potentially other autoimmune disease patients.

Supporting image 1

Figure 1: Our proposed strategy: Enrichment of autologous patient-derived ‘joint-specific’ homing exosomes for the treatment of RA patients.


Disclosures: G. Halpert: None; O. Moskovitch: None; A. Anaki: None; T. Caller: None; O. Gendelman: None; A. watad: None; R. Mehrian-Shai: None; R. Popovtzer: None; B. Guilbord: None; O. Segal: None; H. AMITAL: Janssen, 5.

To cite this abstract in AMA style:

Halpert G, Moskovitch O, Anaki A, Caller T, Gendelman O, watad A, Mehrian-Shai R, Popovtzer R, Guilbord B, Segal O, AMITAL H. The Potential of Autologous Patient-derived Circulating Extracellular Vesicles to Improve Drug Delivery in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/the-potential-of-autologous-patient-derived-circulating-extracellular-vesicles-to-improve-drug-delivery-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-potential-of-autologous-patient-derived-circulating-extracellular-vesicles-to-improve-drug-delivery-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology